SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001347178-20-000018
Filing Date
2020-05-26
Accepted
2020-05-26 07:11:50
Documents
16
Period of Report
2020-05-26
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vnda-20200526.htm   iXBRL 8-K 52112
2 EX-99.1 vanda-form8xk5262020pr.htm EX-99.1 14972
8 GRAPHIC image011.jpg GRAPHIC 15005
  Complete submission text file 0001347178-20-000018.txt   240139

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20200526.xsd EX-101.SCH 2613
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20200526_cal.xml EX-101.CAL 746
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20200526_def.xml EX-101.DEF 1683
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20200526_lab.xml EX-101.LAB 24993
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20200526_pre.xml EX-101.PRE 13226
17 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20200526_htm.xml XML 11302
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 20908105
SIC: 2834 Pharmaceutical Preparations